Semaglutide, potentially with orexin antagonism, shows robust effects in alcohol use disorder

Alcohol Use Disorder (AUD) is a chronic relapsing brain disease affecting millions, with significant health and societal burdens. Current pharmacotherapies often have limited efficacy or undesirable side effects, leaving a substantial treatment gap. Preclinical research suggests that modulating neural circuits involved in reward and motivation, such as the orexin system, could reduce alcohol-seeking behaviors. Additionally, GLP-1 receptor agonists like semaglutide, primarily known for treating obesity and type 2 diabetes, have shown emerging promise in preclinical models for reducing addictive behaviors, including alcohol consumption, by influencing reward pathways and reducing cravings. This study aims to translate these preclinical insights into initial human evidence.

This human laboratory study investigated a combination therapy, including semaglutide, in participants enrolled in a 4-week inpatient treatment program for Alcohol Use Disorder (AUD). The study collected preliminary safety and efficacy data. While specific doses for semaglutide or the orexin antagonist were not detailed in the abstract, the intervention aimed to reduce motivation for alcohol and associated maladaptive behaviors. The primary endpoint for efficacy was the change in alcohol problem severity, measured using the Alcohol Use Disorder Identification Test (AUDIT), a 10-item self-report questionnaire administered at baseline and post-intervention. Adverse events were also monitored.

The study found that semaglutide demonstrated robust therapeutic effects in treatment-seeking participants diagnosed with obesity and alcohol use disorder. While specific quantitative data such as percentages, p-values, or fold-changes were not provided in the abstract, the qualitative assessment indicated a significant positive impact on alcohol-associated maladaptive behaviors. The abstract also noted that adverse events were transient, generally mild to moderate gastrointestinal effects, and occurred more frequently in the semaglutide group. This suggests a tolerability profile consistent with known GLP-1 receptor agonist side effects. The findings support preclinical observations that GLP-1R activation and potentially orexin antagonism can influence reward pathways relevant to AUD. > Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder.